207 related articles for article (PubMed ID: 31473167)
1. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.
Gaudinski MR; Houser KV; Doria-Rose NA; Chen GL; Rothwell RSS; Berkowitz N; Costner P; Holman LA; Gordon IJ; Hendel CS; Kaltovich F; Conan-Cibotti M; Gomez Lorenzo M; Carter C; Sitar S; Carlton K; Gall J; Laurencot C; Lin BC; Bailer RT; McDermott AB; Ko SY; Pegu A; Kwon YD; Kwong PD; Namboodiri AM; Pandey JP; Schwartz R; Arnold F; Hu Z; Zhang L; Huang Y; Koup RA; Capparelli EV; Graham BS; Mascola JR; Ledgerwood JE;
Lancet HIV; 2019 Oct; 6(10):e667-e679. PubMed ID: 31473167
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial.
Mahomed S; Garrett N; Capparelli EV; Osman F; Mkhize NN; Harkoo I; Gengiah TN; Mansoor LE; Baxter C; Archary D; Yende-Zuma N; Samsunder N; Carlton K; Narpala S; McDermott AB; Doria-Rose NA; Moore PL; Morris L; Abdool Karim Q; Mascola JR; Abdool Karim SS
Lancet HIV; 2023 Apr; 10(4):e230-e243. PubMed ID: 37001964
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.
Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Anderson MA; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
PLoS Med; 2024 Jun; 21(6):e1004329. PubMed ID: 38913710
[TBL] [Abstract][Full Text] [Related]
5. A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087).
Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
medRxiv; 2024 Jan; ():. PubMed ID: 38260276
[TBL] [Abstract][Full Text] [Related]
6. Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention.
Mahomed S; Garrett N; Capparelli EV; Osman F; Harkoo I; Yende-Zuma N; Gengiah TN; Archary D; Samsunder N; Baxter C; Mkhize NN; Modise T; Carlton K; McDermott A; Moore PL; Karim QA; Barouch DH; Fast PE; Mascola JR; Ledgerwood JE; Morris L; Abdool Karim SS
J Infect Dis; 2022 Aug; 226(3):510-520. PubMed ID: 35134995
[TBL] [Abstract][Full Text] [Related]
7. Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial.
Mahomed S; Garrett N; Capparelli E; Baxter C; Zuma NY; Gengiah T; Archary D; Moore P; Samsunder N; Barouch DH; Mascola J; Ledgerwood J; Morris L; Abdool Karim S
BMJ Open; 2019 Jul; 9(7):e030283. PubMed ID: 31272988
[TBL] [Abstract][Full Text] [Related]
8. Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial.
Mahomed S; Garrett N; Potloane D; Sikazwe IT; Capparelli E; Harkoo I; Gengiah TN; Zuma NY; Osman F; Mansoor L; Archary D; Myeni N; Radebe P; Samsunder N; Doria-Rose N; Carlton K; Gama L; Koup RA; Narpala S; Serebryannyy L; Moore P; Williamson C; Pozzetto B; Hankins C; Morris L; Karim QA; Abdool Karim S
BMJ Open; 2023 Aug; 13(8):e076843. PubMed ID: 37640457
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
Gaudinski MR; Coates EE; Houser KV; Chen GL; Yamshchikov G; Saunders JG; Holman LA; Gordon I; Plummer S; Hendel CS; Conan-Cibotti M; Lorenzo MG; Sitar S; Carlton K; Laurencot C; Bailer RT; Narpala S; McDermott AB; Namboodiri AM; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
PLoS Med; 2018 Jan; 15(1):e1002493. PubMed ID: 29364886
[TBL] [Abstract][Full Text] [Related]
10. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial.
Mahomed S; Garrett N; Karim QA; Zuma NY; Capparelli E; Baxter C; Gengiah T; Archary D; Samsunder N; Doria-Rose N; Moore P; Williamson C; Barouch DH; Fast PE; Pozzetto B; Hankins C; Carlton K; Ledgerwood J; Morris L; Mascola J; Abdool Karim S
BMJ Open; 2020 Nov; 10(11):e042247. PubMed ID: 33243815
[TBL] [Abstract][Full Text] [Related]
11. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
Julg B; Stephenson KE; Wagh K; Tan SC; Zash R; Walsh S; Ansel J; Kanjilal D; Nkolola J; Walker-Sperling VEK; Ophel J; Yanosick K; Borducchi EN; Maxfield L; Abbink P; Peter L; Yates NL; Wesley MS; Hassell T; Gelderblom HC; deCamp A; Mayer BT; Sato A; Gerber MW; Giorgi EE; Gama L; Koup RA; Mascola JR; Monczor A; Lupo S; Rolle CP; Arduino R; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
Nat Med; 2022 Jun; 28(6):1288-1296. PubMed ID: 35551291
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.
Ledgerwood JE; Coates EE; Yamshchikov G; Saunders JG; Holman L; Enama ME; DeZure A; Lynch RM; Gordon I; Plummer S; Hendel CS; Pegu A; Conan-Cibotti M; Sitar S; Bailer RT; Narpala S; McDermott A; Louder M; O'Dell S; Mohan S; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Mascola JR; Graham BS;
Clin Exp Immunol; 2015 Dec; 182(3):289-301. PubMed ID: 26332605
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.
Awan SF; Pegu A; Strom L; Carter CA; Hendel CS; Holman LA; Costner PJ; Trofymenko O; Dyer R; Gordon IJ; Rothwell RSS; Hickman SP; Conan-Cibotti M; Doria-Rose NA; Lin BC; O'Connell S; Narpala SR; Almasri CG; Liu C; Ko S; Kwon YD; Namboodiri AM; Pandey JP; Arnold FJ; Carlton K; Gall JG; Kwong PD; Capparelli EV; Bailer RT; McDermott AB; Chen GL; Koup RA; Mascola JR; Coates EE; Ledgerwood JE; Gaudinski MR;
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38587079
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Gaudinski MR; Coates EE; Novik L; Widge A; Houser KV; Burch E; Holman LA; Gordon IJ; Chen GL; Carter C; Nason M; Sitar S; Yamshchikov G; Berkowitz N; Andrews C; Vazquez S; Laurencot C; Misasi J; Arnold F; Carlton K; Lawlor H; Gall J; Bailer RT; McDermott A; Capparelli E; Koup RA; Mascola JR; Graham BS; Sullivan NJ; Ledgerwood JE;
Lancet; 2019 Mar; 393(10174):889-898. PubMed ID: 30686586
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
Modjarrad K; Roberts CC; Mills KT; Castellano AR; Paolino K; Muthumani K; Reuschel EL; Robb ML; Racine T; Oh MD; Lamarre C; Zaidi FI; Boyer J; Kudchodkar SB; Jeong M; Darden JM; Park YK; Scott PT; Remigio C; Parikh AP; Wise MC; Patel A; Duperret EK; Kim KY; Choi H; White S; Bagarazzi M; May JM; Kane D; Lee H; Kobinger G; Michael NL; Weiner DB; Thomas SJ; Maslow JN
Lancet Infect Dis; 2019 Sep; 19(9):1013-1022. PubMed ID: 31351922
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.
Houser KV; Gaudinski MR; Happe M; Narpala S; Verardi R; Sarfo EK; Corrigan AR; Wu R; Rothwell RS; Novik L; Hendel CS; Gordon IJ; Berkowitz NM; Cartagena CT; Widge AT; Coates EE; Strom L; Hickman S; Conan-Cibotti M; Vazquez S; Trofymenko O; Plummer S; Stein J; Case CL; Nason M; Biju A; Parchment DK; Changela A; Cheng C; Duan H; Geng H; Teng IT; Zhou T; O'Connell S; Barry C; Carlton K; Gall JG; Flach B; Doria-Rose NA; Graham BS; Koup RA; McDermott AB; Mascola JR; Kwong PD; Ledgerwood JE;
EClinicalMedicine; 2022 Jun; 48():101477. PubMed ID: 35783486
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
Coates EE; Edupuganti S; Chen GL; Happe M; Strom L; Widge A; Florez MB; Cox JH; Gordon I; Plummer S; Ola A; Yamshchikov G; Andrews C; Curate-Ingram S; Morgan P; Nagar S; Collins MH; Bray A; Nguyen T; Stein J; Case CL; Kaltovich F; Wycuff D; Liang CJ; Carlton K; Vazquez S; Mascola JR; Ledgerwood JE;
Lancet Infect Dis; 2022 Aug; 22(8):1210-1220. PubMed ID: 35568049
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
Casazza JP; Cale EM; Narpala S; Yamshchikov GV; Coates EE; Hendel CS; Novik L; Holman LA; Widge AT; Apte P; Gordon I; Gaudinski MR; Conan-Cibotti M; Lin BC; Nason MC; Trofymenko O; Telscher S; Plummer SH; Wycuff D; Adams WC; Pandey JP; McDermott A; Roederer M; Sukienik AN; O'Dell S; Gall JG; Flach B; Terry TL; Choe M; Shi W; Chen X; Kaltovich F; Saunders KO; Stein JA; Doria-Rose NA; Schwartz RM; Balazs AB; Baltimore D; Nabel GJ; Koup RA; Graham BS; Ledgerwood JE; Mascola JR;
Nat Med; 2022 May; 28(5):1022-1030. PubMed ID: 35411076
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
Crowell TA; Colby DJ; Pinyakorn S; Sacdalan C; Pagliuzza A; Intasan J; Benjapornpong K; Tangnaree K; Chomchey N; Kroon E; de Souza MS; Tovanabutra S; Rolland M; Eller MA; Paquin-Proulx D; Bolton DL; Tokarev A; Thomas R; Takata H; Trautmann L; Krebs SJ; Modjarrad K; McDermott AB; Bailer RT; Doria-Rose N; Patel B; Gorelick RJ; Fullmer BA; Schuetz A; Grandin PV; O'Connell RJ; Ledgerwood JE; Graham BS; Tressler R; Mascola JR; Chomont N; Michael NL; Robb ML; Phanuphak N; Ananworanich J;
Lancet HIV; 2019 May; 6(5):e297-e306. PubMed ID: 31000477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
